Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
16 patents granted to the 3 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Eloxx Pharmaceuticals, Inc.’s names, not what it holds today.
Patents granted
16
16 utility, 1976 to Dec 31, 2025
Granted in 2025
none
in the last year the record reads
Applications published
26
since 2001, to Dec 31, 2025
Names they are printed under
3
a former name
By yearGrantedApplications published
'05'06'07'08'09'10'11'12'13'14'15
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
Under which name3 counted
Senesco Technologies, Inc. a former name
US, as the owner printed on each patent
22 publishedSenesco Technologies, Inc. a former name
named as the applicant on its applications, in US
3 publishedSevion Therapeutics, Inc. a former name
US, as the owner printed on each patent
1 publishedNames not counted (2)
Eloxx Pharmaceuticals, Inc.
Most of its patents print IL; this name counts in US. 0 granted and 12 published under it are not counted.
Eloxx Pharmaceuticals, Inc.
Most of its patents print IL; this name counts in US. 7 granted and 2 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Jun 17, 2014 | 8,754,057 | Inhibition of apoptosis-specific eIF-5A(eIF-5A1″) with antisense oligonucleotides and siRNA as anti-inflammatory therapeutics | Pharmaceuticals | Senesco Technologies, Inc. |
| Apr 22, 2014 | 8,703,929 | Compositions comprising siRNA and plasmids | Biotechnology | Senesco Technologies, Inc. |
| Oct 22, 2013 | 8,563,285 | Isoforms of eIF-5A: senescence-induced eIF5A; wounding-induced eIF-5A; growth eIF-5A; and DHS | Biotechnology | Senesco Technologies, Inc. |
| May 21, 2013 | 8,445,638 | Use of a truncated eIF-5A1 polynucleotide to induce apoptosis in cancer cells | Biotechnology | Senesco Technologies, Inc. |
| Aug 14, 2012 | 8,242,256 | siRNA useful to supress expression of EIF-5A1 | Pharmaceuticals | Senesco Technologies, Inc. |
| Jul 31, 2012 | 8,232,455 | Polynucleotides encoding canola DHS and antisense polynucleotides thereof | Biotechnology | Senesco Technologies, Inc. |
| Jun 5, 2012 | 8,193,158 | Use of apoptosis-specific eIF-5A siRNA to down regulate expression of proinflammatory cytokines to treat sepsis | Pharmaceuticals | Senesco Technologies, Inc. |
| Jun 28, 2011 | 7,968,523 | Method for inducing apoptosis using apoptosis-specific EIF5-A | Pharmaceuticals | Senesco Technologies, Inc. |
| Jan 18, 2011 | 7,872,112 | Expression vector encoding apoptosis-specific eIF-5A | Pharmaceuticals | Senesco Technologies, Inc. |
| Feb 16, 2010 | 7,663,028 | Method of increasing seed yield and growth eIF-5A | Biotechnology | Senesco Technologies, Inc. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| May 7, 2015 | 2015/0126582 | Combination Treatment of Multiple Myeloma | Pharmaceuticals | Sevion Therapeutics, Inc. |
| Dec 18, 2014 | 2014/0371299 | Use of Apoptosis-Specific elF-5A siRNA to Down Regulate Expression of Proinflammatory Cytokines to Treat Sepsis | Biotechnology | Senesco Technologies, Inc. |
| Oct 23, 2014 | 2014/0314704 | Treatment of B Cell Lymphomas | Pharmaceuticals | Senesco Technologies, Inc. |
| Oct 2, 2014 | 2014/0296320 | Use Of siRNA To Achieve Down Regulation Of An Endogenous Gene In Combination With The Use of A Sense Construct To Achieve Expression Of A Polynucleotide | Biotechnology | Senesco Technologies, Inc. |
| Jul 31, 2014 | 2014/0212969 | Nucleic Acids, Polypetides, and Methods for Modulating Apoptosis | Pharmaceuticals | Senesco Technologies, Inc. |
| Jun 26, 2014 | 2014/0182014 | Isolated eIF-5A and Polynucleotides Encoding Same | Biotechnology | Senesco Technologies, Inc. |
| Jun 19, 2014 | 2014/0171374 | USE OF A TRUNCATED EIF-5A1 POLYNUCLEOTIDE TO INDUCE APOPTOSIS IN CANCER CELLS | Biotechnology | Senesco Technologies, Inc. |
| Oct 24, 2013 | 2013/0280770 | Transgenic Algae with Enhanced Oil Expression | Biotechnology | Senesco Technologies, Inc. |
| Oct 17, 2013 | 2013/0274318 | Novel Method of Protecting Islet Cells From Apoptosis during the Donor Harvesting Process | Biotechnology | Senesco Technologies, Inc. |
| May 24, 2012 | 2012/0129910 | Inhibition of Apoptosis-Specific eIF-5A(elF-5A1") with Antisense Oligonucleotides and siRNA as Anti-Inflammatory Therapeutics | Pharmaceuticals | Senesco Technologies, Inc. · patent 8,754,057 granted from it |
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.